The multiple sclerosis severity score (MSSS) predicts disease severity over time

Area of Science:

• Neurology
• Clinical Research
• Disease Measurement

Background:

• The Multiple Sclerosis Severity Scale (MSSS) combines disease duration with the Expanded Disability Status Score (EDSS) to assess multiple sclerosis (MS) severity.
• This study investigates the predictive capability of MSSS for long-term disability progression and the impact of current therapies on MS severity.

Purpose of the Study:

• To evaluate the Multiple Sclerosis Severity Scale (MSSS) for predicting disability accrual in individual multiple sclerosis (MS) patients.
• To determine if current disease-modifying therapies influence MS disease severity as measured by the MSSS.

Main Methods:

• Retrospective analysis of MSSS in 195 MS patients treated at a US MS center over two years.
• Detailed analysis of disease course and severity in 10 randomly selected patients.
• 94% of patients received disease-modifying therapies for at least one year.

Main Results:

• The average MSSS for the cohort (n=195) was 48.7, with a mean symptom duration of 9.7 years and EDSS of 3.5.
• In a representative sample (n=10), MSSS assessments remained consistent over 5-12 years, averaging 11.3 points.
• MSSS consistency was observed irrespective of therapeutic interventions.

Conclusions:

• The MSSS shows potential for predicting long-term disease severity in multiple sclerosis (MS).
• Current disease-modifying therapies appear to have a limited impact on MS severity as assessed by the MSSS.
• Further validation in a larger patient cohort is recommended.